Obat Sm-EDTMP pereda nyeri kanker tulang metastasis

Summary

In this presentation, a researcher discusses the development of SM-153, a novel pain relief medication for cancer patients experiencing severe pain due to bone metastasis. Unlike traditional morphine treatments, which lead to addiction, SM-153 offers prolonged relief with a single injection lasting 3-4 months. The drug targets cancerous bone cells using beta particles to destroy them, significantly improving patients' quality of life. Registered with the Indonesian National Drug Agency, SM-153 is covered by BPJS, making it accessible to patients. The study emphasizes the importance of maintaining drug quality and stability, demonstrating excellent results throughout its testing phase.

Takeaways

• 😀 Cancer is a leading cause of death globally, with various types including lung, brain, and breast cancer, often leading to severe pain when metastasized.
• 😀 Traditional pain management for cancer patients often involves morphine, which can lead to addiction and requires frequent re-administration.
• 💉 The SM-153 drug developed by Kiandra Traditional Technology is a novel pain relief option specifically designed for patients with bone metastasis.
• 🌟 SM-153 can provide pain relief for 3-4 months after a single injection, significantly improving the quality of life for patients.
• 🔬 The drug works by targeting cancerous cells in the bones, delivering beta particles that destroy these cells and alleviate pain.
• 📋 The research conducted included rigorous stability testing of SM-153 to ensure its quality and effectiveness over time.
• 🔍 Results from the stability tests showed that SM-153 maintained acceptable pH levels and purity, confirming its high quality.
• 🧪 The study emphasized the importance of quality assurance in pharmaceuticals to prevent discrepancies in drug efficacy.
• 🏥 SM-153 is registered with regulatory bodies, ensuring it meets all necessary specifications for safety and effectiveness.
• 💡 The research highlights the potential of SM-153 as a safer alternative for pain management in cancer patients, reducing reliance on addictive painkillers.

Q & A

What is the main purpose of the research presented by Masker?

The main purpose of the research is to ensure the quality of the pain-relief drug labeled SM-153, which is used for patients suffering from metastatic bone cancer.

What types of cancer are mentioned in the presentation?

The presentation mentions several types of cancer, including lung cancer, brain cancer, nasopharyngeal cancer, breast cancer, and prostate cancer.

What are the typical treatments for pain relief in cancer patients?

Typically, morphine injections are used for pain relief, but they only provide temporary relief and can lead to addiction due to repeated use.

How does the drug SM-153 work to alleviate pain?

SM-153 works by targeting cancerous cells in the bones. When injected, it travels through the bloodstream and, upon reaching cancerous areas, it releases beta particles that destroy the cancer cells, leading to pain relief.

What regulatory approval has SM-153 received?

SM-153 is registered with the Indonesian Food and Drug Authority (BPOM) under license number DKL 1612 4843 A1, issued in 2016, and is commercially known as Tibone KF.

What methodology was used in the research to test the drug's stability?

The methodology involved stability testing over six days, where important parameters like pH levels were measured and compared to established specifications.

What were the findings regarding the drug's quality during the stability tests?

The findings indicated that the drug maintained its quality over six days, with pH levels remaining stable within acceptable limits and purity levels above 99%.

How does the quality assurance process impact the use of SM-153?

The quality assurance process is crucial to ensure that SM-153 meets safety and efficacy standards, thereby preventing any discrepancies in its quality and ensuring patient safety.

What is the significance of the drug's long-lasting effects?

The long-lasting effects of SM-153, which can provide pain relief for 3-4 months after a single injection, significantly improve the quality of life for patients with metastatic bone cancer.

What does the conclusion of the presentation emphasize?

The conclusion emphasizes the importance of maintaining drug quality through rigorous testing and compliance with specifications, highlighting that SM-153 is safe for patient use prior to its expiration.